Inactive Instrument

CanaQuest Medical Corp Stock Other OTC

CA01551X1087

Valuation: CanaQuest Medical Corp

Market Cap	3.83M 3.4M 3.18M 2.9M 5.44M 368M 5.52M 38.39M 14.88M 188M 14.36M 14.05M 605M	P/E 2017	-1.01x	P/E 2018	-1.17x
Enterprise Value	3.98M 3.54M 3.31M 3.02M 5.66M 383M 5.74M 39.93M 15.47M 195M 14.94M 14.62M 629M	EV / Sales 2017	-	EV / Sales 2018	-
Free-Float	43.35%	Yield 2017 *	-	Yield 2018	-

* Estimated data More valuation ratios

Latest news: CanaQuest Medical Corp

24-06-11	CanaQuest Medical Corp. Announces Appointment of Dr. Paul Dick, Chairman of Advisory Board	CI
23-10-31	NHL Alumni Association Partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in Former NHL Players	CI
23-10-25	CanaQuest Medical Corp. cancelled the transaction announced on October 26, 2022	CI
23-09-19	CanaQuest Medical Corp. Announces Award of European Cannabinoid Patent	CI
22-12-08	CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD	CI
22-10-25	CanaQuest Medical Corp. announced a financing transaction	CI
22-09-08	CanaQuest Medical Corp. Launches Mentanine (R) (Cannabidiol + IP Formula) in the US	CI
21-04-07	CanaQuest Medical Corp. Appoints Rob Rinderman as New Director of Communications	CI
21-03-11	Canaquest Signs Medicinal Cannabis Education Partnership with the Canadian Cannabis Dispute Resolution Centre	CI
21-02-02	CANAQUEST MEDICAL CORP Announces New Production and Distribution Agreement with PurCann Pharma and SiliCycle Inc	CI
20-07-14	CanaQuest Medical Corp. Files A Provisional Cannabidiol/Omega-3 Patent, Trade Named Mentanine®	CI
20-02-06	CanaQuest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol®	CI
19-04-08	CanaQuest Medical Corp. will Change its Ticker to CANQ.F from ADYNF	CI

More news

Press Releases: CanaQuest Medical Corp

24-06-11	CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials	AQ
23-09-20	CANAQUEST Announces Award of European Cannabinoid Patent	AQ
23-07-27	CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health and Pharma for their 8th Annual Healthcare and Pharmaceutical Program	AQ
22-08-08	CanaQuest Medical : Interim Consolidated Consolidated Financial Statements (unaudited) - June 30, 2022	PU
22-07-18	CanaQuest Medical : Attorney Letter	PU

More press releases

Managers and Directors: CanaQuest Medical Corp

Manager	Title	Age	Since
Paul Ramsay CEO	Chief Executive Officer	66	-
Ross Eastley DFI	Director of Finance/CFO	78	2008-12-31
Eddie Francis COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Paul Ramsay CHM	Chairman	66	2008-10-06
Richard Rusiniak BRD	Director/Board Member	77	2008-10-06
Ross Eastley BRD	Director/Board Member	78	2008-12-31

More insiders

CanaQuest Medical Corp is a Canada-based biopharmaceutical company specializing in the development of cannabinoid-based therapeutics. The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post-Traumatic Stress Disorder (PTSD). It has created a natural formulation derived from cannabidiol + proprietary API composition. The Company is focused on CQ-001, its proprietary drug candidate that combines cannabidiol (CBD) with essential fatty acids (Omega-3s). CQ-001 is positioned for clinical trials targeting epilepsy. The Company is also developing a nutraceutical version of this formulation, called Mentanine, which is scheduled for clinical studies to explore its potential use for various conditions. The Company has a wholly owned subsidiary, ADC BioMedical Corp.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CANAQUEST MEDICAL CORP	-.--%	-.--%	-	-	21
ELI LILLY AND COMPANY	-0.62%	-0.10%	+50.70%	+114.07%	1,031B
JOHNSON & JOHNSON	-2.30%	-3.90%	+39.50%	+66.07%	638B
ABBVIE INC.	-0.63%	-1.94%	+12.26%	+74.38%	462B
MERCK & CO., INC.	-1.03%	-2.88%	+71.35%	+39.69%	359B
ROCHE HOLDING AG	-0.03%	-3.91%	+34.28%	+39.35%	335B
NOVARTIS AG	-1.58%	+0.39%	+17.92%	+25.77%	273B
ASTRAZENECA PLC	-2.02%	-3.20%	+7.60%	+8.38%	253B
AMGEN INC.	-3.38%	+0.29%	+44.32%	+51.54%	228B
GILEAD SCIENCES, INC.	-1.04%	-2.56%	+32.88%	+96.82%	185B
Average	-0.62%	-0.36%	+34.53%	+57.34%	418.21B
Weighted average by Cap.	-0.21%	-0.35%	+38.05%	+69.18%

	2017	2018
Net sales	-	-
Net income	-2.59M -2.3M -2.15M -1.96M -3.68M -249M -3.73M -25.94M -10.05M -127M -9.71M -9.5M -409M	-1.1M -979K -915K -835K -1.57M -106M -1.59M -11.05M -4.28M -54.05M -4.13M -4.04M -174M
Net Debt	91.34K 81.24K 75.91K 69.23K 130K 8.8M 132K 916K 355K 4.48M 343K 335K 14.44M	154K 137K 128K 116K 218K 14.79M 222K 1.54M 597K 7.54M 577K 564K 24.27M

CanaQuest Medical Corp Stock Other OTC

Stocks

CA01551X1087

Pharmaceuticals

Valuation: CanaQuest Medical Corp

Latest news: CanaQuest Medical Corp

Press Releases: CanaQuest Medical Corp

Managers and Directors: CanaQuest Medical Corp

Alternative Medicine

Financials

Company Profile